25-NET-04-CPI-PMC (CRN09682-191): A Phase 1 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Soli

Grants and Contracts Details

StatusActive
Effective start/end date10/27/25 → 10/27/27

Funding

  • Crinetics Pharmaceuticals: $2.00